The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price decrease of -35.74%. However, over the past six months, we’ve seen a stronger performance of -42.75%. The price of ARWR leaped by -20.05% over the last 30 days. And in the last five days, it has surged by 2.46%.
The market performance of Arrowhead Pharmaceuticals Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $30.41 on 07/16/24, while the lowest value for the same duration was $9.57 on 04/07/25.
52-week price history of ARWR Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Arrowhead Pharmaceuticals Inc’s current trading price is -60.28% away from its 52-week high, while its distance from the 52-week low is 26.23%. The stock’s price range during this period has varied between$9.57 and $30.41. The Arrowhead Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.52 million for the day, a figure considerably higher than their average daily volume of 2.1 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Arrowhead Pharmaceuticals Inc (ARWR) has experienced a quarterly decline of -38.24% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.66B and boasts a workforce of 609 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 18.19, with a change in price of -6.20. Similarly, Arrowhead Pharmaceuticals Inc recorded 2,017,268 in trading volume during the last 100 days, posting a change of -33.92%.
ARWR’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ARWR stands at 16.58. Similarly, the long-term debt-to-equity ratio is also 16.43.
ARWR Stock Stochastic Average
As of today, Arrowhead Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 20.46%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 41.28%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 32.07% and 32.24%, respectively.
